## **Publication of Annual Report and Notice of AGM**

**Paris, France and Camberley, UK – 24 May 2019 –** Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces that the Company's Annual Report and Accounts ("Annual Report") for the year ended 31 December 2018 has been published and uploaded to the Company's website. The Annual Report will also be posted in hard copy to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs). The Notice of the Annual General Meeting (AGM) and a Form of Proxy have been posted to shareholders.

Electronic copies of these documents are available on the Company's website at <u>www.novacyt.com</u>. Alternatively, a hardcopy is available from either 13 Avenue Morane Saulnier, 78140 Vélizy-Villacoublay, France or Unit 1, Watchmoor Point, Watchmoor Road, Camberley, Surrey, GU15 3AD or will be posted upon request from <u>investor.relations@novacyt.com</u>.

The AGM will be held on 19 June, at 2.00 p.m. (Paris time) Cabinet Racine, Paris, 40 rue de Courcelles, 75008, Paris, France.

- End -

<u>Contacts</u> Novacyt SA

ΝΟΥΛΟ

GROUP

Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1276 600081

**SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)** Matthew Johnson / Jamie Spotswood (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470

**WG Partners (Joint Broker)** Nigel Birks / Chris Lee / Claes Spång +44 (0)203 705 9330

**FTI Consulting (International)** Brett Pollard / Victoria Foster Mitchell +44 (0)20 3727 1000 brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com Mary.whittow@fticonsulting.com

**FTI Consulting (France)** Arnaud de Cheffontaines / Astrid Villette +33 (0)147 03 69 47 / +33 (0)147 03 69 51 <u>arnaud.decheffontaines@fticonsulting.com</u> / <u>astrid.villette@fticonsulting.com</u>

**About Novacyt Group** 



The Novacyt Group is a rapidly growing, international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com